Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05507151 · ClinicalTrials.gov registry record
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
A clinical trial of Non-alcoholic Fatty Liver Disease, sponsored by West Virginia University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05507151: Recruiting study of Non-alcoholic Fatty Liver Disease, sponsored by West Virginia University.
NCT05507151 is a study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by West Virginia University. The registered enrollment target is 30 participants, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05507151, a study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by West Virginia University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach. Realizing there is a knowledge gap in applying ESG to morbidly obese patients with NAFLD, the investigators propose studying the efficacy of weight control and functional outcomes of ESG. This prospective pilot study is aimed to study the safety profiles, quality of life, and changes and improvements in the anthropometric, metabolic, and biochemical changes in these patients.
Primary Outcome
The CAP measures ultrasonic attenuation in the liver at 3.5 MHz using signals acquired by the FibroScan® M probe based on vibration-controlled transient elastography. The final CAP value, which ranges from 100 to 400 decibels per metre (dB/m), is the median of individual measurements. Higher measure indicates higher portion of liver affected by fatty change.
Conditions Studied
Interventions
- PROCEDURE Endoscopic Sleeve Gastroplasty
Study Locations (1)
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2026-05 |
What NCT05507151 shows while recruiting
NCT05507151 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Endoscopic Sleeve Gastroplasty is the first listed.
NCT05507151 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT05507151 about?
NCT05507151 is a clinical study titled "Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis". Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach. Realizing there is a knowledge gap in applying ESG to morbidly obese patients with NAFLD, the investigat...
What is the current status of trial NCT05507151?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2022-08-24. Estimated completion is 2026-05.
What conditions does trial NCT05507151 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT05507151?
The interventions under investigation include: Endoscopic Sleeve Gastroplasty (PROCEDURE).
Who is sponsoring clinical trial NCT05507151?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05507151 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05507151's enrollment target sits among peer trials
30 47th of 57 higher than 10 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI